Search

Onze Lieve Vrouwe Gasthuis, HagaZiekenhuis, Dijklander Ziekenhuis, The Netherlands Cancer Institute, Isala, Maasstad Hospital, Medisch Spectrum Twente, University Medical Center Groningen, Leiden University Medical Center, Hospital Universitario La Fe, Ospedale Policlinico San Martino, University Hospital Carl Gustav Carus, Medical University Innsbruck, Spaarne Gasthuis, Zaans Medical Center, Alrijne Hospital, Albert Schweitzer Hospital, Maastricht University Medical Center, Noordwest Ziekenhuisgroep, and Prof. Dr. Marcus J. Schultz, Professor of Intensive Care Medicine, Principal Investigator

Academisch Ziekenhuis Maastricht, The Netherlands Cancer Institute, University Medical Center Nijmegen, Erasmus Medical Center, University Ghent, KU Leuven, Centre Oscar Lambret, Gasthuis Zusters Antwerpen, University College, London, Cliniques universitaires Saint-Luc- Université Catholique de Louvain, University Hospital Dresden, University Hospital Tuebingen, Heidelberg University, Catholic University of the Sacred Heart, and Institut du Cancer de Montpellier - Val d'Aurelle

European Commission, CRIS Cancer Foundation, National Cancer Institute, France, Rennes University Hospital, University Hospital, Essen, Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron, The Netherlands Cancer Institute, Servicio Madrileño de Salud, Madrid, Spain, Hospital Universitario 12 de Octubre, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Medical University of Vienna, FAKULTNI NEMOCNICE OLOMOUC, International Kidney Cancer Coalition, Association pour la Recherche sur les Tumeurs du Rein, Resilience, PRIMAA, and Queen Mary University of London

Netherlands Cancer Institute - NKI

Erasmus Medical Center, The Netherlands Cancer Institute, and Florit Marcuse, Principal investigator, MD PhD

Leiden University Medical Center, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Radboud University Medical Center, The Netherlands Cancer Institute, Het Zwarte Gat, Columbia University, and Peter Blanken, PhD, Senior researcher

University of Birmingham, University Hospital Birmingham NHS Foundation Trust, Royal Marsden NHS Foundation Trust, University Hospital Padova, Campus Bio-Medico University, The Netherlands Cancer Institute, KU Leuven, Heidelberg University, Dana-Farber/Brigham and Women's Cancer Center, Emory University, Mayo Clinic, Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, The Cleveland Clinic, M.D. Anderson Cancer Center, University of Southern California, Ohio State University, Ottawa Hospital Research Institute, McGill University, Peter MacCallum Cancer Centre, Australia, and Royal Prince Alfred Hospital, Sydney, Australia

Eindhoven University of Technology, Roche BV Netherlands, Maxima Medical Center, Zuyderland Medisch Centrum, Maastricht University Medical Center, St. Anna Ziekenhuis, Geldrop, Netherlands, The Netherlands Cancer Institute, and Volkher Scharnhorst, Prof. Dr. (Clinical Chemist)

Gustave Roussy, Cancer Campus, Grand Paris, German Cancer Research Center, Oslo universitetssykehus HF, The Netherlands Cancer Institute, Hospital del Mar Research Institute, Istituto Europeo di Oncologia, European Organisation for Research and Treatment of Cancer - EORTC, UNICANCER, EAPC, Institut Curie, EUROPEAN CANCER ORGANISATION, DIGICORE/IFO, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Alleanza Contro il Cancro, Istituti Fisioterapici Ospitalieri, STICHTING NEDERLANDS INSTITUUT VOOR ONDERZOEK VAN DE GEZONDHEIDSZORG, University of Milan, SporeData OÜ, ORGANISATION OF EUROPEAN CANCER INSTITUTES, FEDERAZIONE ITALIANA DELLE ASSOCIAZIONI DI VOLONTARIATO IN ONCOLOGIA, Medical University Innsbruck, SDRUZHENIE ASOTSIATSIA NA PATSIENTITE SONKOLOGICHNI ZABOLYAVANIA I PRIYATELI, FEDERATIA ASOCIATIILOR BOLNAVILOR DE CANCER, University of Leeds, The Leeds Teaching Hospitals NHS Trust, and Region Hovedstaden (Bispebjerg Hospital & Rigshospitalet)

UMC Utrecht, Catharina Ziekenhuis Eindhoven, Institute Verbeeten, Elisabeth-TweeSteden Ziekenhuis, Leiden University Medical Center, Radiotherapeutic Institute Friesland, Medical Centre Leeuwarden, Radiotherapy Group Deventer, Deventer Ziekenhuis, Rijnstate Hospital, Erasmus Medical Center, The Netherlands Cancer Institute, Isala, University Medical Center Groningen, Ziekenhuisgroep Twente, and Hanneke W. M. van Laarhoven, Prof. dr.

Alert Hospital, Ethiopia, Armauer Hansen Research Institute, Ethiopia, Uppsala University, and The Netherlands Cancer Institute

University Hospital of North Norway, Alesund Hospital, Vestre Viken Hospital Trust, University Hospital, Akershus, Helse Nord-Trøndelag HF, Helse Stavanger HF, Haukeland University Hospital, Sorlandet Hospital HF, Ullevaal University Hospital, Molde Hospital, Helse Fonna, Nordlandssykehuset HF, Volda Hospital, Kristiansund Hospital, Vastra Gotaland Region, Skane University Hospital, Karolinska University Hospital, Ôrebro University Hospital, Gävle Hospital, University Hospital, Linkoeping, Odense University Hospital, Aalborg University Hospital, Rigshospitalet, Denmark, National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos, Kantonsspital Winterthur KSW, University Hospital, Basel, Switzerland, Insel Gruppe AG, University Hospital Bern, Kantonsspital Graubünden, Freiburger Spital, Klinik Hirslanden, Zurich, Kantonsspital Olten, Spital STS AG, Ente Ospedaliero Cantonale, Bellinzona, Cantonal Hospital of St. Gallen, St. Olavs Hospital, Oslo University Hospital, Rijnstate Hospital, Isala, Zuyderland Medisch Centrum, The Netherlands Cancer Institute, St. Antonius Hospital, Amphia Hospital, Medisch Spectrum Twente, and Erasmus Medical Center

Erasmus Medical Center, The Netherlands Cancer Institute, Leiden University Medical Center, and UMC Utrecht

University of Bern, The Netherlands Cancer Institute, University of Lausanne Hospitals, University Hospital, Geneva, University of Zurich, and Olgun Elicin, Principal Investigator and Sponsor

Personal Genome Diagnostics, The Netherlands Cancer Institute, and Miriam Koopman, Prof. dr.

The Netherlands Cancer Institute

M.D. Anderson Cancer Center and The Netherlands Cancer Institute

Amsterdam University Medical Center, Erasmus Medical Center, Maastricht University Medical Center, Radboud University Medical Center, The Netherlands Cancer Institute, and Leiden University Medical Center

Amsterdam University Medical Center, The Netherlands Cancer Institute, The Elisabeth-TweeSteden Hospital, Erasmus Medical Center, Medical Center Haaglanden, Isala, Leiden University Medical Center, Maastricht University Medical Center, Medisch Spectrum Twente, Radboud University Medical Center, University Medical Center Groningen, and Dr. F.Y.F.L. de Vos, medical oncologist

The Netherlands Cancer Institute

Canisius-Wilhelmina Hospital, The Netherlands Cancer Institute, and St. Antonius Hospital

Universitaire Ziekenhuizen KU Leuven, Radboud University Medical Center, The Netherlands Cancer Institute, University Hospital, Basel, Switzerland, University of Zurich, University Medical Center Groningen, Isala, Tianjin Medical University Cancer Institute and Hospital, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Cardiff University, The Leeds Teaching Hospitals NHS Trust, The Christie NHS Foundation Trust, Cambridge University Hospitals NHS Foundation Trust, Hospital Israelita Albert Einstein, University of Pennsylvania, Liverpool Hospital, South Western Sydney Local Health District, MVR Cancer Centre and Research Institute India, H. Lee Moffitt Cancer Center and Research Institute, Oslo University Hospital, Christian Medical College, Vellore, India, Fudan University, Swiss Institute of Bioinformatics, Guangdong Provincial People's Hospital, National Institute of Technology Calicut, Maastricht University, and Andre Dekker, Professor of Clinical Data Science

University Of Perugia, University of Chieti, Medical University of Vienna, The Netherlands Cancer Institute, Monash University, and Gianmaria Cammarota, MD, PhD, Prof Gianmaria Cammarota

Amsterdam UMC, location VUmc, Centre for Human Drug Research, Netherlands, The Netherlands Cancer Institute, and Lioe-Fee de Geus-Oei, MD PhD, Principal Investigator

Vall d'Hebron Institute of Oncology and The Netherlands Cancer Institute

University of Pavia, Policlinico di Bari Ospedale Giovanni Paolo XXIII, Biomeris srl, The Netherlands Cancer Institute NKI, University of Haifa, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), IBM Research, Bitsens JSC, Poznań University of Technology, Deontics LTD, Associazione Italiana Malati di Cancro AIMAC, and Universidad Politecnica de Madrid

The Netherlands Cancer Institute, Erasmus Medical Center, San Gerardo Hospital, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Charles University, Czech Republic, and Frederic Amant, MD, PhD

The Netherlands Cancer Institute, The Institute of Endemic Diseases (IEND), University of Khartoum, Kenya Medical Research Institute, Makerere University, and University of Gondar

The Netherlands Cancer Institute, Technical University of Munich, and Institut de Radioprotection et de Surete Nucleaire

German Cancer Research Center, German Sport University Cologne (DSHS), Cologne, Germany, Cabrini Health (CAB), Malvern, Australia, Karolinska Institute (KI), Stockholm, Sweden, Netherlands Cancer Institute (NKI), Amsterdam, The Netherlands, Heidelberg University Clinic and National Center for Tumor Diseases, Heidelberg, Germany, Fundacion Onkologikao (ONK), San Sebastian, Spain, Associação de Investigação e Cuidados de Suporte em Oncologia (AISCO), Nova de Gaia, Portugal, and Dr. Anne May, Prof. Dr.

Dutch Cancer Society, The Netherlands Cancer Institute, and lmvanvliet, Assistant Professor

UMC Utrecht, The Netherlands Cancer Institute, Erasmus Medical Center, Leiden University Medical Center, Maastro Clinic, The Netherlands, Maastricht University Medical Center, and University Medical Center Groningen

German Cancer Research Center, Australian Catholic University, Karolinska Institutet, The Netherlands Cancer Institute, Medical University of Gdansk, Fundación Onkologikoa Fundazioa, Europa Donna, German Sport University, Cologne, University Hospital Heidelberg, Nurogames GmbH, Cologne, and Dr. Anne May, Cancer Epidemiologist

The Netherlands Cancer Institute, Radboud University Medical Center, and Kom Op Tegen Kanker

The Netherlands Cancer Institute, Borstkanker Onderzoek Groep, Comprehensive Cancer Centre The Netherlands, Koningin Wilhelmina Fonds, World Cancer Research Fund International, L-Nutra Inc, and J.R. Kroep, Drs J.R. Kroep

UMC Utrecht, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Rijnstate Hospital, Jeroen Bosch Ziekenhuis, Flevoziekenhuis, Catharina Ziekenhuis Eindhoven, Meander Medical Center, Ziekenhuis Amstelland, Amphia Hospital, Spaarne Gasthuis, Canisius-Wilhelmina Hospital, Amsterdam UMC, location VUmc, and The Netherlands Cancer Institute

University of Liverpool, The Netherlands Cancer Institute, Northern Care Alliance NHS Foundation Trust, and University of Manchester

Hotel Dieu Hospital and The Netherlands Cancer Institute

Radboud University Medical Center, The Netherlands Cancer Institute, Catharina Ziekenhuis Eindhoven, ZonMw: The Netherlands Organisation for Health Research and Development, and Esther Lems, Medical doctor, Principal Investigator

The Netherlands Cancer Institute, Sunnybrook Health Sciences Centre, M.D. Anderson Cancer Center, The Christie NHS Foundation Trust, Royal Marsden NHS Foundation Trust, Medical College of Wisconsin, Elekta Limited, Odense University Hospital, Radboud University Medical Center, Radiotherapiegroep, Jules Bordet Institute, University Hospital Tuebingen, Radiotherapeutic Institute Friesland, Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute), IRCCS Sacro Cuore Don Calabria di Negrar, Austin Health, Princess Margaret Hospital, Canada, Università degli Studi di Brescia, and Helena M Verkooijen, Prof. Dr.

Amsterdam UMC, location VUmc, The Netherlands Cancer Institute, Radboud University Medical Center, Leiden University Medical Center, and Prof.dr. H.P. Beerlage, Urologist, Head of Department of Urology

The Netherlands Cancer Institute

Radboud University Medical Center, The Netherlands Cancer Institute, Royal Marsden NHS Foundation Trust, and C. Verhoef, Prof. dr. C. Verhoef, MD, PhD

The Netherlands Cancer Institute

The Netherlands Cancer Institute, Maastricht University Medical Center, and Zuyderland Medical Centre

Haukeland University Hospital, Maastricht University Medical Center, Brno University Hospital, Holycross Cancer Center Kielce, Medical University of Lublin, Hospital del Mar, Hospital Vall d'Hebron, Royal Cornwall Hospitals Trust, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), The Netherlands Cancer Institute, Canisius-Wilhelmina Hospital, Catharina Ziekenhuis Eindhoven, Erasmus Medical Center, and Leiden University Medical Center

The Netherlands Cancer Institute and Renske Altena, MD PhD

Hoffmann-La Roche, Amsterdam UMC, location VUmc, The Netherlands Cancer Institute, and A.J.M. van den Eertwegh, Medical Oncologist

Dutch Breast Cancer Screening Organisations, Dutch Reference Centre for Screening, National Institute for Public Health and the Environment (RIVM), The Netherlands Cancer Institute, University Medical Center Nijmegen, Jeroen Bosch Ziekenhuis, Albert Schweitzer Hospital, Hospital Group Twente (ZGT), Amsterdam UMC, location VUmc, Maastricht University Medical Center, ZonMw: The Netherlands Organisation for Health Research and Development, Dutch Cancer Society, Pink Ribbon Inc., A Sister's Hope, Bayer, Stichting Kankerpreventie Midden-West, Volpara Solutions, and C.H. van Gils, Professor of Clinical Epidemiology of Cancer

The Netherlands Cancer Institute and Diakonessenhuis, Utrecht